Non-Invasive Monitoring Systems (NIMU) 10-K 13 Nov 19 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2019	Nov. 08, 2019	Oct. 25, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	NON INVASIVE MONITORING SYSTEMS INC /FL/
Entity Central Index Key	0000720762
Document Type	10-K
Document Period End Date	Jul. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Public Float			$ 3,900,000
Entity Common Stock, Shares Outstanding		154,810,655
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Current assets
Cash	$ 353	$ 90
Prepaid expenses, deposits, and other current assets	5	17
Current assets - discontinued operations	3	3
Total current assets	361	110
Total assets	361	110
Current liabilities - discontinued operations
Accounts payable and accrued expenses	225	1,482
Current liabilities - discontinued operations	55	181
Total current liabilities	280	1,663
Long Term liabilities
Notes payable - Related party		2,075
Notes Payable - other		50
Total long term liabilities		2,125
Total liabilities	280	3,788
Commitments and Contingencies (Note 10)
Shareholders' equity (deficit)
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 and 79,007,423 shares issued and outstanding as of July 31, 2019 and 2018, respectively	1,548	790
Additional paid in capital	26,574	21,930
Accumulated deficit	(28,041)	(26,463)
Total shareholders' equity (deficit)	81	(3,678)
Total liabilities and shareholders' equity	361	110
Series B Preferred Stock [Member]
Shareholders' equity (deficit)
Preferred Stock, value
Total shareholders' equity (deficit)
Series C Convertible Preferred Stock [Member]
Shareholders' equity (deficit)
Preferred Stock, value		62
Series D Convertible Preferred Stock [Member]
Shareholders' equity (deficit)
Preferred Stock, value		$ 3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	154,810,655	79,007,423
Common stock, shares outstanding	154,810,655	79,007,423
Series B Preferred Stock [Member]
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	100	100
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference	$ 10	$ 10
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	0	62,048
Preferred stock, shares issued	0	62,048
Preferred stock, shares outstanding	0	62,048
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	0	5,500
Preferred stock, shares issued	0	2,782
Preferred stock, shares outstanding	0	2,782

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Operating costs and expenses
General and administrative	$ 446	$ 178
Total operating costs and expenses	446	178
Operating loss	(446)	(178)
Interest and other expense
Loss on extinguishment of debt	(1,066)
Interest expense	(93)	(220)
Total interest and other expense	(1,159)	(220)
Loss from continuing operations	(1,605)	(398)
Loss from discontinued operations	(10)	(47)
Net loss	$ (1,615)	$ (445)
Weighted average number of common shares outstanding - basic and diluted	123,262,000	79,007,000
Basic and diluted net loss from continuing operations	$ (0.01)	$ (0.01)
Basic and diluted net loss from discontinued operations	0	0
Basic and diluted loss per common share	$ (0.01)	$ (0.01)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Jul. 31, 2017		$ 62	$ 3	$ 790	$ 21,930	$ (26,018)	$ (3,233)
Balance, beginning shares at Jul. 31, 2017	100	62,048	2,782	79,007,423
Net loss						(445)	(445)
Balance, ending at Jul. 31, 2018		$ 62	$ 3	$ 790	21,930	(26,463)	(3,678)
Balance, ending shares at Jul. 31, 2018	100	62,048	2,782	79,007,423
Issuance of common stock for cash				$ 86	514		600
Issuance of common stock for cash, shares				8,571,428
Issuance of common stock in exchange for extinguishment of debt, accrued interest and accounts payable				$ 533	4,266		4,799
Issuance of common stock in exchange for extinguishment of debt, accrued interest and accounts payable, shares				53,321,804
Redemption of Series C Preferred Stock		$ (62)				37	(25)
Redemption of Series C Preferred Stock, shares		(62,048)
Conversion of Series D Preferred Stock			$ (3)	$ 139	(136)
Conversion of Series D Preferred Stock, shares			(2,782)	13,910,000
Net loss						(1,615)	(1,615)
Balance, ending at Jul. 31, 2019				$ 1,548	$ 26,574	$ (28,041)	$ 81
Balance, ending shares at Jul. 31, 2019	100			154,810,655

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Operating activities
Net Loss	$ (1,615)	$ (445)
Add back: loss attributable to discontinued operations	10	47
Adjustments to reconcile net loss to net cash used in operating activities
Loss on extinguishment of debt	1,066
Changes in operating assets and liabilities
Prepaid expenses, deposits and other current assets	12	(10)
Accounts payable and accrued expenses	111	234
Net cash used in continuing operations	(416)	(174)
Net cash used in discontinued operations	(21)	(47)
Net cash used in operating activities	(437)	(221)
Financing activities
Proceeds from issuance of common stock	600
Proceeds from note payable - related party	100	300
Net cash provided by financing activities	700	300
Net increase in cash from continuing operations	263	79
Cash, beginning of year	90	11
Net cash change from discontinued operations
Cash, end of year	353	90
Supplemental disclosure of non-cash financing activity
Accounts payable and accrued expenses extinguished for issuance of common stock	1,508
Notes payable extinguished for issuance of common stock	2,225
Accrued redemption for Series D Preferred Stock	25
Accrued expense exchanged for inventory	$ 15

Organization and Business

Organization and Business	12 Months Ended
	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. ORGANIZATION AND BUSINESS Organization. ® Business. Going Concern. The Company is seeking potential mergers, acquisitions and strategic collaborations. There is no assurance that the Company will be successful in this regard, and, if not successful, that it will be able to continue its business activities. The accompanying consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Discontinued Operations. Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at July 31, 2019. See Discontinued Operations Note 4. Equity Exchange Agreement. On August 4, 2019, IRAFG delivered to the Company notice of termination of the Exchange Agreement pursuant to Section 8.01(b)(i) of that agreement due to the failure of the Exchange to have closed on or prior to the Outside Date. No termination fees, penalties or other amounts are payable by the Company in respect of such termination.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation. Use of Estimates. Cash and Cash Equivalents. Inventories. Income Taxes. The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2015 to 2018 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision. Warranties. ® Stock-based compensation. Fair Value of Financial Instruments. Level 1 — quoted prices in active markets for identical assets or liabilities. Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. Financial instruments recognized in the consolidated balance sheet consist of cash, prepaid expenses, deposits, and other current assets. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments. The respective carrying value of the notes payable – related party and notes payable – other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. The following table presents changes in Level 3 financial liabilities measured at fair value on a recurring basis: Level 3 Fair value of promissory notes at July 31, 2018 $ 2,125,000 Additions: 100,000 Reductions: (2,225,000) Changes in fair value - Fair value at July 31, 2019 $ - Loss Contingencies. Recent Accounting Pronouncements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases Leases

Inventories

Inventories	12 Months Ended
	Jul. 31, 2019
Inventory Disclosure [Abstract]
Inventories	3. INVENTORIES On May 3, 2019 the Company exchanged inventory for forgiveness of $15,000 of accrued unpaid rent. The Company had previously written off the value of this inventory resulting in a gain on the forgiveness of approximately $15,000.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Jul. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	4. DISCONTINUED OPERATIONS On May 3, 2019 the Company exchanged its inventory for forgiveness of accrued unpaid rent. Concurrent with the exchange management with the appropriate level of authority determined to discontinue the operations of the product segment. The detail of the consolidated balance sheets, the consolidated statement of operations and consolidated cash flows for the discontinued operations is as stated below: As of July 31, 2019 As of July 31, 2018 Current assets – discontinued operations Prepaid expenses $ 3 $ 3 Total current assets – discontinued operations 3 3 Total assets – discontinued operations $ 3 $ 3 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 55 $ 181 Total current liabilities – discontinued operations 55 181 Total liabilities – discontinued operations $ 55 $ 181 For the year ended 2019 For the year ended 2018 Selling, general and administrative expenses $ (37 ) $ (47 ) Other income 12 - Gain on exchange of inventory 15 - Loss from discontinued operations (10 ) (47 ) Basic and diluted loss per common share $ (0.00 ) $ (0.00 ) For the year ended 2019 For the year ended 2018 Cash used in operations for discontinued operations: Loss from discontinued operations $ (10 ) $ (47 ) Gain on exchange of inventory (15 ) - Accounts payable and accrued expenses 4 - Cash used in discontinued operations $ (21 ) $ (47 ) The Company plans to realize or collect prepaid expense and resolve any remaining accounts payable and accrued expenses from discontinued operations during the next six months.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	5. STOCK-BASED COMPENSATION The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company did not record any stock-based compensation during the twelve months ended July 31, 2019 and 2018. In November 2010, the Company’s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of July 31, 2019. The Company did not grant any stock options during the twelve months ended July 31, 2019 or 2018. As of July 31, 2019, there were no outstanding stock options and there were no unrecognized costs related to outstanding stock options.

Notes Payable

Notes Payable	12 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	6. NOTES PAYABLE The Company entered into various notes payable with related parties from 2010 to 2018 with an aggregate principal total of $2,175,000 and with an unrelated third party for $50,000 for total principal amount of $2,225,000. The interest rate was 11% and the maturity date was July 31, 2020. The Company could prepay these notes in advance of the maturity date without premium or penalty. On December 21, 2018, the Company issued 50,584,413 shares of Common Stock in exchange for the extinguishment of debt and related accrued interest totaling approximately $3,541,000 resulting in a loss on the extinguishment of $1,066,000. The Company incurred interest expense related to the Credit Facility and notes payable of $93,000 and $220,000 for the year ended July 31, 2019 and 2018, respectively. The Company maintains a Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock (“Frost Gamma”), and Hsu Gamma Investments, LP, an entity controlled by the Company’s Chairman and Interim CEO (“Hsu Gamma” and together with Frost Gamma, the “Lenders”), pursuant to which the Lenders have provided a revolving credit line (the “Credit Facility”) in the aggregate principal amount of up to $1.0 million, secured by all of the Company’s personal property. The interest rate payable on amounts outstanding under the Credit Facility is 11% per annum and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2020 (the “Credit Facility Maturity Date”). The balance of the principal due under the Credit Facility was $0 and $1,000,000 at July 31, 2019 and 2018, respectively.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Jul. 31, 2019
Equity [Abstract]
Shareholders' Equity	7. SHAREHOLDERS’ EQUITY The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters. Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared. Series C Preferred Stock is redeemable by the Company at a price of $0.10 per share upon 30 days prior written notice. This series has a liquidation value of $1.00 per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $0.10 per share, if declared. Each share of Series C Preferred Stock is convertible into 25 shares of the Company’s common stock upon payment of a conversion premium of $4.20 per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all outstanding shares of Series C Preferred Stock were redeemed by the Company following 30 days written notice. The redemption amount for the 62,048 Series C Preferred Stock was approximately $25,000 at a rate of $0.40 per share of which approximately $15,000 was paid and approximately $10,000 is included in accrued expenses at July 31, 2019. The redeemed Series C Preferred Stock were then cancelled following the redemption. Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $1,500 per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company’s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all holders of the 2,782 outstanding shares of Series D Preferred Stock converted their shares to common stock. As a result, the Company issued 13,910,000 common shares. No preferred stock dividends were declared for the years ended July 31, 2019 and 2018. On December 21, 2018, the Company entered into stock purchase agreements with Frost Gamma Investments Trust, a trust controlled by Dr. Philip Frost, and Jane Hsiao, Ph.D., the Company’s Chairman and Interim CEO. As a result of the Purchase Agreements, the Company issued and sold to FGIT and Dr. Hsiao an aggregate of 8,571,428 shares of the Company’s common stock, par value $0.01 per share (at a purchase price of $0.07 per share for total aggregate amount of $600,000). On December 21, 2018, the Company entered into a Debt Exchange Agreement with Frost Gamma Investments Trust, Dr. Jane Hsiao, Hsu Gamma Investments LP and Marie Wolf (collectively, the “Creditors”), pursuant to which the Company issued to the Creditors aggregate of 50,584,413 shares of Common Stock (the “Exchange Shares”) in exchange the extinguishment of the credit facility and notes payable totaling $2,225,000 and related accrued interest of approximately $1,316,000. In addition, the Company issued an additional 2,737,391 shares of common stock to Hsu Gamma Investments LP and Frost Gamma Investments Trust, for in exchange for the extinguishment of rent payable totaling approximately $192,000. The Company issued the Exchange Shares at a price of $0.07 per share. The fair value of the stock issued was based on the closing price of the Company’s stock on the day of the debt exchange which was $0.09 per share resulting in a $1,066,000 loss on the extinguishment of debt.

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	12 Months Ended
	Jul. 31, 2019
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Share	8. BASIC AND DILUTED LOSS PER SHARE Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the years ended July 31, 2019 and 2018, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive. Potential common shares not included in calculating diluted net loss per share are as follows: July 31, 2019 July 31, 2018 Series C Preferred Stock - 1,551,200 Series D Preferred Stock - 13,910,000 Total - 15,461,200

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jul. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	9. RELATED PARTY TRANSACTIONS Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each stockholders, current or former officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded medical device company. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company’s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staff of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staff was shared by the Company and TransEnterix. The Chief Financial Officer continues to serve as the Chief Financial Officer of Cocrytal Pharma, Inc., a clinical stage biotechnology company, and in which Steve Rubin and Jane Hsiao, serve on the Board. Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as the Chief Legal Officer of TransEnterix. The Company recorded additions to general and administrative costs and expenses to account for the sharing of costs under these arrangements of $5,000 and $5,000 for the years ended July 31, 2019 and 2018, respectively. Aggregate accounts payable to TransEnterix totaled approximately $1,600 and $800 at July 31, 2019 and 2018, respectively. The Company signed a five year lease for office space in Miami, Florida with a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. The rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, were approximately $1,250 per month and then continued on a month-to-month basis. In February 2016 the rent was reduced to $0 per month. For the years ended July 31, 2019 and 2018, the Company did not record any rent expense related to the Miami lease. At July 31, 2019 and 2018, approximately $0 and $76,000 in rent was payable. The Company signed a three year lease for warehouse space in Hialeah, Florida with a company jointly controlled by Dr. Frost and Dr. Jane Hsiao, the Company’s Chairman and Interim CEO. The rental payments under the Hialeah warehouse lease, which commenced February 1, 2009 and expired on January 31, 2012, were approximately $5,000 per month for the first year and were subsequently on a month-to-month basis following the expiration of the lease. The Company vacated the Hialeah warehouse in September 2014 and entered into a new lease with an unrelated third party. The Company did not record any rent expense related to the Hialeah lease for the years ended July 31, 2019 and 2018, respectively. At July 31, 2019 and 2018, approximately $0 and $115,000 in rent was payable under the previous Hialeah lease. The Company is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. (“OPKO”) and the Company are under common control and OPKO has a one percent ownership interest in the Company that OPKO has accounted for as an equity method investment due to the ability to significantly influence the Company.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Leases The Company was under an operating lease agreement for our corporate office space that expired in 2012. The lease currently continues on a month to month basis at no cost. We housed our inventory in approximately 4,000 square feet of warehouse space in Pembroke Park, Florida. The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we exercised our option to renew the lease and extended the expiration to September 15, 2017. Following the expiration, we have remained on a month-to-month term. On May 3, 2019 the Company exchanged inventory for forgiveness of $15,000 of accrued unpaid rent. The Company had previously written off the value of this inventory resulting in a gain on the forgiveness of approximately $15,000. The Company no longer leases this Pembroke Park warehouse following the sale of inventory. Product Development and Supply Agreement. In September 2007, the Company entered into a Product Development and Supply Agreement (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan (“Sing Lin”). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party’s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date. Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $471,000. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $150,000 of the tooling cost upon execution of the Agreement and $150,000 upon the Company’s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009. Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East. The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through July 31, 2019, the Company had paid Sing Lin $1.7 million in connection with orders placed through that date. As of July 31, 2019, the Company has approximately $41,000 of payables due to Sing Lin. As of July 31, 2019, aggregate minimum future purchases under the Agreement totaled approximately $13.9 million. As of July 31, 2019, the Company had not placed orders sufficient to meet the first-year or second-year minimum purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of November 11, 2019, Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies. The Company believes that Sing Lin in no longer in business.

Risks and Uncertainties and Con

Risks and Uncertainties and Concentrations of Risk	12 Months Ended
	Jul. 31, 2019
Risks and Uncertainties [Abstract]
Risks and Uncertainties and Concentrations of Risk	11. RISKS AND UNCERTAINTIES AND CONCENTRATIONS OF RISK Financial instruments that potentially subject the Company to risk consist principally of purchases and advances to contract manufacturer.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Jul. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	12. ACCOUNTS PAYABLE AND ACCCRUED EXPENSES Accounts payable and accrued expenses from continuing operations are summarized in the following table (in thousands): July 31, 2019 July 31, 2018 Accounts payable $ 198 $ 252 Accrued interest - 1,223 Accrued redemption 10 - Accrued other 17 7 Total $ 225 $ 1,482

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	13. INCOME TAXES The Company accounts for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The accounting for uncertain tax positions guidance under ASC 740 requires that we recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The application of this guidance does not affect the Company’s financial position, results of operations or cash flows for the years ended July 31, 2019 and 2018. The Company files its tax returns in the U.S. federal jurisdiction, Canada federal jurisdiction and with various U.S. states and the Ontario province of Canada. The Company is subject to tax audits in all jurisdictions for which it files tax returns. Tax audits by their very nature are often complex and can require several years to complete. There are currently no tax audits that have commenced with respect to income tax or any other returns in any jurisdiction. Tax years ranging from 2015 to 2018 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. Because the Company is carrying forward income tax attributes, such as net operating losses and tax credits from 2014 and earlier tax years, these attributes can still be audited when utilized on returns filed in the future. It is the Company’s policy to include income tax interest and penalties expense in its tax provision. On December 22, 2017, the “Tax Cuts and Jobs Act” (Tax Reform), was signed into law. In addition to changes or limitations to certain tax deductions, the Tax Cuts and Jobs Act permanently lowered the corporate tax rate to 21% from the existing maximum rate of 35%, effective for tax years commencing January 1, 2018. As a result of the reduction of the corporate tax rate to 21%, the Company reduced the amount of its net deferred tax assets by $2 million, with a corresponding decrease in the valuation allowance, which resulted in no net tax adjustment. The difference between income taxes at the statutory federal income tax rate of 21% in 2019 and 2018 and income taxes reported in the consolidated comprehensive statements of operations are attributable to the following (in thousands): July 31, 2019 % July 31, 2018 % Income tax benefit at the federal statutory rate from continuing operations $ (337 ) 21.0 $ (85 ) 21.0 State income taxes, net of effect of federal taxes (23 ) 1.5 (17 ) 4.0 Loss from extinguishment of debt 224 (13.9 ) - - Expired net operating losses 138 (8.6 ) - - Tax Reform – Reduction in tax rate - - 2,011 (505 ) Change in valuation allowance (2 ) - (1,909 ) 479 Provision for income tax – continuing operations - - - - Income tax benefit at the federal statutory rate for discontinued operations (2 ) 21.0 (10 ) 21.0 State income taxes, net of effect of federal taxes - 5.3 (3 ) 5.0 Change in valuation allowance 2 (26.3 ) 13 (26.0 ) Provision for income tax – discontinued operations - - - - Total $ - - $ - - The tax effects of temporary differences that give rise to significant portions of the deferred tax assets consist of the following (in thousands): July 31, 2019 July 31, 2018 Federal and State net operating loss $ 4,146 $ 4,146 Foreign net operating loss 18 18 Stock-based compensation and other 116 116 4,280 4,280 Less: Valuation allowance (4,280 ) (4,280 ) Net deferred tax asset $ – $ – At July 31, 2019, the Company had available Federal and State net operating loss carry forwards of approximately $16.4 million and foreign net operating loss carry forwards of approximately $0.1 million which expire in various years beginning in 2020. Net operating loss carry forwards generated in 2019 and later years never expire. However, these net operating losses can only be used to reduce taxable income by 80 percent. The net operating loss carry forwards may be subject to limitation due to change of ownership provisions under section 382 of the Internal Revenue Code and similar state provisions. A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, management has determined that a full $4.3 million valuation allowance at July 31, 2019 ($4.3 million at July 31, 2018) was necessary. The decrease in the valuation allowance for the years ended July 31, 2019 and 2018 were approximately $0.0 million and $1.9 million (which includes a reduction of $2.0 million resulting from the change in federal tax rate from Tax Reform), respectively. The Company paid no taxes for the years 2019 or 2018.

Subsequent Events

Subsequent Events	12 Months Ended
	Jul. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	14. SUBSEQUENT EVENTS Equity Exchange Agreement. On December 3, 2018, the Company entered into an Equity Exchange Agreement (the “Exchange Agreement”) with IRA Financial Trust Company, a South Dakota trust corporation, IRA Financial Group LLC, a Florida limited liability company, and their respective equity holders. The Company, IRA Financial and the equity holders subsequently amended the Exchange Agreement on three occasions to extend the outside date for consummation of the Exchange, with the last such extension expiring on July 3, 2019. On August 4, 2019, IRA Financial Group delivered to the Company notice of termination of the Exchange Agreement pursuant to Section 8.01(b)(i) of that agreement due to the failure of the Exchange to have closed on or prior to the Outside Date. No termination fees, penalties or other amounts are payable by the Company in respect of such termination.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Consolidation	Consolidation.
Use of Estimates	Use of Estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents.
Inventories	Inventories.
Income Taxes	Income Taxes. The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2015 to 2018 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.
Warranties	Warranties. ®
Stock-based Compensation	Stock-based compensation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. Level 1 — quoted prices in active markets for identical assets or liabilities. Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. Financial instruments recognized in the consolidated balance sheet consist of cash, prepaid expenses, deposits, and other current assets. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments. The respective carrying value of the notes payable – related party and notes payable – other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. The following table presents changes in Level 3 financial liabilities measured at fair value on a recurring basis: Level 3 Fair value of promissory notes at July 31, 2018 $ 2,125,000 Additions: 100,000 Reductions: (2,225,000) Changes in fair value - Fair value at July 31, 2019 $ -
Loss Contingencies	Loss Contingencies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases Leases

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis	The following table presents changes in Level 3 financial liabilities measured at fair value on a recurring basis: Level 3 Fair value of promissory notes at July 31, 2018 $ 2,125,000 Additions: 100,000 Reductions: (2,225,000) Changes in fair value - Fair value at July 31, 2019 $ -

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Jul. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Balance Sheets of Discontinued operations	As of July 31, 2019 As of July 31, 2018 Current assets – discontinued operations Prepaid expenses $ 3 $ 3 Total current assets – discontinued operations 3 3 Total assets – discontinued operations $ 3 $ 3 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 55 $ 181 Total current liabilities – discontinued operations 55 181 Total liabilities – discontinued operations $ 55 $ 181
Schedule of Statement of Operations for Discontinued Operations	For the year ended 2019 For the year ended 2018 Selling, general and administrative expenses $ (37 ) $ (47 ) Other income 12 - Gain on exchange of inventory 15 - Loss from discontinued operations (10 ) (47 ) Basic and diluted loss per common share $ (0.00 ) $ (0.00 )
Schedule of Cash Flows of Discontinued Operations	For the year ended 2019 For the year ended 2018 Cash used in operations for discontinued operations: Loss from discontinued operations $ (10 ) $ (47 ) Gain on exchange of inventory (15 ) - Accounts payable and accrued expenses 4 - Cash used in discontinued operations $ (21 ) $ (47 )

Basic and Diluted Loss Per Sh_2

Basic and Diluted Loss Per Share (Tables)	12 Months Ended
	Jul. 31, 2019
Earnings Per Share [Abstract]
Schedule of Common Shares Not Included in Calculation of Diluted Net Loss Per Share	Potential common shares not included in calculating diluted net loss per share are as follows: July 31, 2019 July 31, 2018 Series C Preferred Stock - 1,551,200 Series D Preferred Stock - 13,910,000 Total - 15,461,200

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Jul. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses from continuing operations are summarized in the following table (in thousands): July 31, 2019 July 31, 2018 Accounts payable $ 198 $ 252 Accrued interest - 1,223 Accrued redemption 10 - Accrued other 17 7 Total $ 225 $ 1,482

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Federal Income Tax Rate and Income Taxes	The difference between income taxes at the statutory federal income tax rate of 21% in 2019 and 2018 and income taxes reported in the consolidated comprehensive statements of operations are attributable to the following (in thousands): July 31, 2019 % July 31, 2018 % Income tax benefit at the federal statutory rate from continuing operations $ (337 ) 21.0 $ (85 ) 21.0 State income taxes, net of effect of federal taxes (23 ) 1.5 (17 ) 4.0 Loss from extinguishment of debt 224 (13.9 ) - - Expired net operating losses 138 (8.6 ) - - Tax Reform – Reduction in tax rate - - 2,011 (505 ) Change in valuation allowance (2 ) - (1,909 ) 479 Provision for income tax – continuing operations - - - - Income tax benefit at the federal statutory rate for discontinued operations (2 ) 21.0 (10 ) 21.0 State income taxes, net of effect of federal taxes - 5.3 (3 ) 5.0 Change in valuation allowance 2 (26.3 ) 13 (26.0 ) Provision for income tax – discontinued operations - - - - Total $ - - $ - -
Schedule of Deferred Tax Assets	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets consist of the following (in thousands): July 31, 2019 July 31, 2018 Federal and State net operating loss $ 4,146 $ 4,146 Foreign net operating loss 18 18 Stock-based compensation and other 116 116 4,280 4,280 Less: Valuation allowance (4,280 ) (4,280 ) Net deferred tax asset $ – $ –

Organization and Business (Deta

Organization and Business (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (1,615)	$ (445)
Accumulated deficit	(28,041)	(26,463)
Cash	353	90
Working capital	81
Inventory

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Cash	$ 353	$ 90
Inventories
Material warranty costs
Accrued warranty		$ 12
Accrued warranty reserve	$ 12
Exer-Rest Products [Member] | Domestic [Member]
Product warranties period	2 years
Exer-Rest Products [Member] | U.S. Outside [Member]
Product warranties period	1 year
Minimum [Member]
Income tax examination year under examination	2015
Maximum [Member]
Income tax examination year under examination	2018

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	12 Months Ended
	Jul. 31, 2019USD ($)
Fair value of promissory notes at July 31, 2018	$ 2,125
Additions:	100
Reductions:	(2,225)
Changes in fair value
Fair value at July 31, 2019

Inventories (Details Narrative)

Inventories (Details Narrative) $ in Thousands	May 03, 2019USD ($)
Inventory Disclosure [Abstract]
Inventory accrued unpaid rent on forgiveness	$ 15
Inventory written off value in gain on forgiveness	$ 15

Discontinued Operations - Sched

Discontinued Operations - Schedule of Balance Sheets of Discontinued Operations (Details) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Prepaid expenses	$ 3	$ 3
Total current assets - discontinued operations	3	3
Total assets - discontinued operations	3	3
Accounts payable and accrued expenses	55	181
Total current liabilities - discontinued operations	55	181
Total liabilities - discontinued operations	$ 55	$ 181

Discontinued Operations - Sch_2

Discontinued Operations - Schedule of Statement of Operations for Discontinued Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Selling, general and administrative expenses	$ (37)	$ (47)
Other income	12
Gain on exchange of inventory	15
Loss from discontinued operations	$ (10)	$ (47)
Basic and diluted loss per common share	$ 0	$ 0

Discontinued Operations - Sch_3

Discontinued Operations - Schedule of Cash Flows of Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Loss from discontinued operations	$ (10)	$ (47)
Gain on exchange of inventory	(15)
Accounts payable and accrued expenses	4
Cash used in discontinued operations	$ (21)	$ (47)

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Nov. 30, 2010
Stock based compensation
Number of stock options granted
Stock options, outstanding
2011 Stock Incentive Plan [Member] | Maximum [Member]
Maximum number of shares authorized for issuance under the plan			4,000,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($) $ in Thousands	Dec. 21, 2018	Jul. 31, 2019	Jul. 31, 2018
Short-term Debt [Line Items]
Proceeds from unrelated third party		$ 100	$ 300
Debt conversion of common stock issued	50,584,413
Accrued interest related debt	$ 3,541
Loss on debt extinguishment		1,066
Interest expenses		93	220
Lenders [Member]
Short-term Debt [Line Items]
Line of credit		0	$ 1,000
Note and Security Agreement [Member] | Dr Phillip Frost [Member]
Short-term Debt [Line Items]
Ownership percentage	10.00%
Note and Security Agreement [Member] | Lenders [Member]
Short-term Debt [Line Items]
Line of credit principal amount	$ 10,000
Credit facility interest rate	11.00%
Increase in credit facility rate	16.00%
Credit facility maturity date	Jul. 31, 2020
2010 to 2018 [Member]
Short-term Debt [Line Items]
Aggregate principal amount		2,175
Proceeds from unrelated third party		50
Total principal amount		$ 2,225
Debt instrument interest rate		11.00%
Debt instrument maturity date		Jul. 31, 2020

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 21, 2018	Jul. 31, 2019	Jul. 31, 2018	Feb. 28, 2019
Subsidiary, Sale of Stock [Line Items]
Stock redemption, amount		$ (25)
Common stock share outstanding		154,810,655	79,007,423
Common stock shares issued		154,810,655	79,007,423
Dividends, preferred stock
Common stock par value		$ 0.01	$ 0.01
Number of common stock issued during period, value		$ 600
Accrued interest			$ 1,223
Purchase Agreement [Member] | Dr. Philip Frost, and Jane Hsiao [Member]
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued during period	8,571,428
Common stock par value	$ 0.01
Common stock price per shares	$ 0.07
Number of common stock issued during period, value	$ 600
Debt Exchange Agreement [Member] | Creditors [Member]
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued during period	50,584,413
Notes payable	$ 2,225
Accrued interest	$ 1,316
Debt Exchange Agreement [Member] | Hsu Gamma Investments LP and Frost Gamma Investments Trust [Member]
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued during period	2,737,391
Common stock price per shares	$ 0.07
Debt exchange price per shares	$ 0.09
Debt extinguishment amount	$ 1,066
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value		$ 100
Dividends payable amount per share		$ 10
Stock redemption, shares
Stock redemption, amount
Number of common stock issued during period
Number of common stock issued during period, value
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value		$ 1
Dividends payable amount per share		0.10
Preferred stock, redemption price per share		$ 0.10
Convertible preferred stock, shares issued upon conversion		25
Preferred stock conversion premium price per share		$ 4.20
Preferred stock, conversion basis		Each share of Series C Preferred Stock is convertible into 25 shares of the Company's common stock upon payment of a conversion premium of $4.20 per share of common stock.
Stock redemption, shares		62,048
Stock redemption, amount		$ (62)
Share price per share		$ 0.40
Preferred stock, redemption price		$ 15
Accrued expenses		$ 10
Number of common stock issued during period
Number of common stock issued during period, value
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value		$ 1,500
Convertible preferred stock, shares issued upon conversion		5,000
Preferred stock, conversion basis		Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company's common stock.
Stock redemption, shares
Stock redemption, amount
Common stock share outstanding				2,782
Common stock shares issued				13,910,000
Number of common stock issued during period
Number of common stock issued during period, value

Basic and Diluted Loss Per Sh_3

Basic and Diluted Loss Per Share - Schedule of Common Shares Not Included in Calculation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Class of Stock [Line Items]
Total		15,461,200
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Total		1,551,200
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Total		13,910,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2016	Jul. 31, 2019	Jul. 31, 2018
Related Party Transaction [Line Items]
General and administrative costs and expenses		$ 446,000	$ 178,000
Rent expenses	$ 0
TransEnterix [Member]
Related Party Transaction [Line Items]
General and administrative costs and expenses		5,000	5,000
Aggregate accounts payable		1,600	800
Miami Lease [Member]
Related Party Transaction [Line Items]
Rent expenses
Rent payable		$ 0	76,000
Miami Lease [Member] | Dr Phillip Frost [Member]
Related Party Transaction [Line Items]
Lease term		5 years
Beneficial ownership percentage		10.00%
Lease expire date		Dec. 31, 2012
Payments for rent		$ 1,250
Hialeah Lease [Member]
Related Party Transaction [Line Items]
Rent expenses
Rent payable		$ 0	$ 115,000
Hialeah Lease [Member] | Dr. Philip Frost, and Jane Hsiao [Member]
Related Party Transaction [Line Items]
Lease term		3 years
Lease expire date		Jan. 31, 2012
Payments for rent		$ 5,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Thousands	May 03, 2019USD ($)	Sep. 30, 2007USD ($)	Jul. 31, 2019USD ($)ft²
Area of land | ft²			4,000
Lease expiration date description			The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we exercised our option to renew the lease and extended the expiration to September 15, 2017.
Inventory accrued unpaid rent forgiveness	$ 15
Inventory written off value in gain on forgiveness	$ 15
Purchase obligation			$ 13,900
Sing Lin [Member]
Payments to suppliers			1,700
Payables to customers			41
Product Development and Supply Agreement [Member]
Manufacturing costs		$ 471
Cost of utilities		150
Payments on approval of product prototype concepts and designs		$ 150
Product Development and Supply Agreement [Member] | Exer Rest Units [Member]
Purchase obligation, due in next twelve months			2,600
Purchase obligation, due in second year			4,100
Purchase obligation, due in third year			$ 8,800

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 198	$ 252
Accrued interest		1,223
Accrued redemption	10
Accrued other	17	7
Total	$ 225	$ 1,482

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income tax likelihood percentage description	Greater than 50 percent
Income tax, description	On December 22, 2017, the "Tax Cuts and Jobs Act" (Tax Reform), was signed into law. In addition to changes or limitations to certain tax deductions, the Tax Cuts and Jobs Act permanently lowered the corporate tax rate to 21% from the existing maximum rate of 35%, effective for tax years commencing January 1, 2018.
Corporate tax rate percentage	21.00%	21.00%
Reduction in deferred tax assets	$ 2,000
Operating loss carryforwards expire, description	Net operating loss carry forwards generated in 2019 and later years never expire.
Reduce taxable income percentage description	Reduce taxable income by 80 percent.
Deferred tax assets, valuation allowance	$ 4,280	$ 4,280
Decrease in valuation allowance	0	1,900
Reduction in change in federal tax rate from tax reform		$ 2,013
Federal and State Tax Authority [Member]
Operating loss carryforwards	16,400
Foreign Tax Authority [Member]
Operating loss carryforwards	$ 100

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax Rate and Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Tax Reform - Reduction in tax rate		$ 2,013
Income tax benefit at the federal statutory rate, rate	21.00%	21.00%
Continuing Operations [Member]
Income tax benefit at the federal statutory rate	$ (337)	$ (85)
State and local income taxes, net of effect of federal taxes	(23)	(17)
Loss from extinguishment of debt	224
Expired net operating losses	138
Tax Reform - Reduction in tax rate		2,011
Change in valuation allowance	(2)	(1,909)
Provision for income tax
Income tax benefit at the federal statutory rate, rate	21.00%	21.00%
State income taxes, net of effect of federal taxes, rate	1.50%	4.00%
Loss from extinguishment of debt, rate	(13.90%)	0.00%
Expired net operating losses, rate	(8.60%)	0.00%
Tax Reform - Reduction in tax rate, rate	0.00%	(505.00%)
Change in valuation allowance, rate	0.00%	479.00%
Provision for income tax, rate	0.00%	0.00%
Discontinued Operations [Member]
Income tax benefit at the federal statutory rate	$ (2)	$ (10)
State and local income taxes, net of effect of federal taxes		(3)
Change in valuation allowance	2	13
Provision for income tax
Total
Income tax benefit at the federal statutory rate, rate	21.00%	21.00%
State income taxes, net of effect of federal taxes, rate	5.30%	5.00%
Change in valuation allowance, rate	(26.30%)	(26.00%)
Provision for income tax, rate	0.00%	0.00%
Total	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Income Tax Disclosure [Abstract]
Federal and State net operating loss	$ 4,146	$ 4,146
Foreign net operating loss	18	18
Stock-based compensation and other	116	116
Deferred tax assets gross, total	4,280	4,280
Less: Valuation allowance	(4,280)	(4,280)
Net deferred tax asset